top of page

Nobel laureate Carolyn Bertozzi on the launch of Firefly Bio and the science of degrader antibody conjugates

Firefly Bio emerged from stealth yesterday with a $94M series A. Co-Founder Carolyn Bertozzi introduces the company and explains the idea behind combining the science of antibody-drug conjugates with protein degraders.


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page